Asset
Lepzacitinib
Aclaris Therapeutics Inc. Common Stock
Revenue
No revenue reported in loaded filings.
Clinical trials (1)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT04598269 | phase2 | completed | 2020-09-30 | 2021-04-08 | Aclaris Therapeutics, Inc. | Study of ATI-1777 in Adult Patients With Moderate or Severe Atopic Dermatitis |
FDA applications (0)
This company has no applications containing this asset.